A 12-week trial found 10g of daily creatine increased lean mass and strength in adults 45 to 65, with greater results when paired with resistance training.
In September 2026, the Journal of the International Society of Sports Nutrition published a 12-week randomized trial. The study found that creatine monohydrate increased lean tissue and improved muscular strength in sedentary adults aged 45 to 65.
Historically, standard clinical guidance viewed creatine primarily as a performance product for young athletes. The previous medical consensus focused almost exclusively on progressive resistance training to manage muscle preservation in middle age. Supplementation was rarely recommended as a mainstream clinical tool for ordinary adults looking to maintain functional capability. Medical professionals typically dismissed nutritional adjuncts for midlife populations, treating strength maintenance strictly through behavioral lifestyle changes.
The recent clinical trial provides precise data on midlife physical adaptation. The researchers examined creatine use in healthy, sedentary adults between the ages of 45 and 65. A total of 73 participants initially began the process. Ultimately, 64 individuals completed the main intervention and were included in the final analysis. The group of completers featured a balanced but slightly female-skewed demographic, comprising 40 women and 24 men.
The investigators offered the subjects a specific choice before the active trial period started. Participants could either join a structured exercise and diet program, or they could remain in a non-exercise baseline condition. The non-exercise participants did not receive any structured exercise or diet intervention. The researchers then randomized the subjects to receive either creatine or a placebo within those distinct groups. This specific structural distinction matters greatly for interpreting the results. The supplementation was strictly randomized, but the exercise participation relied entirely on self-selection.
The researchers identified several concrete outcomes regarding daily supplementation and physical capability. The trial documented the following specific discoveries and updated protocols:
The trial clarifies that changes in midlife body composition respond best to a combined approach. The non-exercise participants did see measurable strength improvements from the supplement alone. However, the active participants experienced larger overall gains in lean tissue and body-fat reduction. The structured exercise protocol involved supervised resistance and aerobic training three times per week.
Participants completed three sets of 10 repetitions for each specific resistance exercise. They also managed progressive load increases at intervals of one to two weeks. The routine included approximately 20 minutes of aerobic work. This aerobic training was performed at 60 to 80 percent of the participants' heart-rate reserve. The active group followed a calorie-deficit diet alongside their physical training. The 1.27 kilograms of lean tissue gained by the active creatine group contrasted sharply with the active placebo group. The exercise and diet placebo group gained only about 0.14 kilograms of lean tissue during the same timeframe.
The physical strength benefits recorded in the study did not translate equally to all forms of fitness. Creatine did not produce a clear additional benefit for general aerobic capacity, despite the marked improvements in strength and muscular endurance. The active participants improved their raw lifting strength, but their cardiovascular performance showed no specific creatine-related advantage.
The researchers also measured various cognitive tests, mood metrics and blood markers during the trial. The authors explicitly described these individual cognitive and biomarker findings as exploratory. They stated clearly that these secondary results require confirmation in future clinical research. The cognitive and metabolic outcomes should not be treated as established, definitive benefits. The study analyzed many exploratory outcomes without a prespecified across-outcome multiplicity adjustment.
The new trial adds to growing scientific interest in creatine as a healthy aging adjunct. However, it does not prove that creatine specifically treats the shifting hormonal environment of perimenopause and menopause. The study enrolled a general age cohort rather than a specific menopause-defined group. It does not show that creatine reduces menopausal symptoms, reverses hormonal changes, or improves sleep. Creatine is not a menopause treatment, and it should not be marketed as a solution for every midlife concern.
Research summaries focused specifically on postmenopausal women have noted more modest physiological changes over time. A separate reported meta-analysis covering five trials and 338 participants examined women taking creatine. That analysis found a mean lean-mass advantage of approximately 0.37 kilograms compared with control conditions. The broader evidence base suggests a highly practical pattern for midlife women. Creatine may support lean mass goals, but the clearest case involves pairing it with consistent resistance training rather than relying on it alone.
The 12-week study duration leaves several long-term physiological questions unanswered. It cannot establish whether these specific lean-tissue changes persist over a longer period. It also cannot prove whether creatine actively slows age-related muscle loss over multiple decades. The participant pool was relatively small, with only 13 to 20 individuals assigned to each treatment group.
The lack of randomization for the exercise component introduces potential behavioral variables. Participants chose their activity level, meaning pre-existing motivation, health or lifestyle differences might have influenced the final outcomes. The study used DXA scans to measure lean tissue and fat-free mass. Lean mass measurements include water and other non-muscle components, so they should not automatically be interpreted as pure contractile muscle tissue. A scale increase after starting creatine does not automatically indicate fat gain.
Safety remains a primary concern for any new daily supplementation protocol. A 2025 analysis led by Richard Kreider and colleagues reviewed 685 clinical trials. That comprehensive review reported no significant difference in the rate of reported side effects between creatine and placebo groups. The broader analysis is relevant to general safety context, but it does not eliminate the need to consider an individual’s medical history.
The new 12-week trial did observe small serum creatinine increases of less than 0.15 milligrams per deciliter. Creatinine levels can affect estimated glomerular filtration rates. The study authors noted that filtration values remained above 60 mL/min/1.73 m² and interpreted the changes very cautiously. The study did not measure cystatin C or use a directly measured glomerular filtration rate. People with known kidney disease or unexplained kidney function changes should always discuss supplementation with a clinician first.
Midlife women looking to preserve strength should view this clinical data systematically. The most defensible takeaway is that creatine serves as an adjunct to consistent training rather than a shortcut around it. A realistic framework begins with prioritizing progressive resistance exercise. Women should also maintain adequate protein intake and a sustainable eating pattern.
The 10-gram daily dose used in this specific trial is not a universal prescription for every woman. Body size, diet, training status and medical context all dictate appropriate individual usage. Women new to strength work can begin with manageable full-body movements. Exercises like squats, rows, presses, hinges and loaded carries build a solid mechanical foundation. You can increase resistance gradually as your technique and physical confidence improve.
The principal investigator for the trial, Richard Kreider, is a professor and director of the Exercise and Sport Nutrition Lab at Texas A&M University. He has studied creatine for more than 30 years. The researchers concluded that 10 grams per day of creatine increased lean tissue mass, strength and muscular endurance in middle-aged and older adults. The paper’s conclusion was cautious, noting that creatine “may help” middle-aged and older adults maintain muscle mass and strength.
Going forward, clinicians will increasingly position creatine as an evidence-based adjunct to resistance training for midlife body composition, moving it permanently beyond its reputation as an athlete-exclusive product.
When conflicting information about perimenopause, menopause and postmenopause complicates your daily health choices, assessing new supplements requires careful perspective. We address your questions about changes in strength, muscle, body composition, metabolism or weight, helping you apply clinical evidence to your physical routine without relying on marketing hype. Explore Resources
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources